Immodulon further strengthens leadership team

UK cancer immunotherapy firm Immodulon has appointed Richard Couch as chief technology officer and Owen Vaughan as chief regulatory officer.

These key appointments will support the advancement of IMM-101 into a pivotal pancreatic cancer trial and follow the recent recruitment of Dr Josefine Roemmler-Zehrer, as chief medical officer, the company noted.

Mr Couch brings over 30 years’ pharmaceutical experience across regulatory, drug development and commercialization to Immodulon. He spent 15 years at Celgene, most recently as vice president, global regulatory CMC before founding R3LS, a CMC consultancy. At Celgene, which was acquired by Bristol Myers Squibb (NYSE: BMY), Mr Couch built and led the global regulatory CMC group responsible for developing and implementing CMC strategies for small molecules, biologics and cell therapies. During his time, he oversaw the development of 20 clinical compounds from Phase I clinical development through to commercialization. He started his career at Merck & Co (NYSE: MRK).